<DOC>
	<DOCNO>NCT02213796</DOCNO>
	<brief_summary>This prospective , noncomparative study ass pharmacodynamics meropenem early phase severe sepsis septic shock critically ill patient intensive care unit . Clinical laboratory data age , sex , body weight , electrolyte , vital sign , APACHE II score , SOFA score , BUN , Cr blood culture collect . Twelve patient enrol study . Meropenem pharmacokinetic carry first second dose 1g meropenem administration . Blood sample ( approximately 3 ml ) obtain direct venepuncture follow time : 0 , 0.25 , 0.5 , 1 , 1.25 , 1.5 , 2 , 2.5 , 3 , 4 , 5 , 8 , 8.5 , 9 , 9.5 , 10 , 12 , 14 16 h. Meropenem assay perform modified method Ozkan et al . ( Biomed . Chromatogr. , 2001 ) . The pharmacokinetics meropenem model concentration-time profile use compartmental model . Monte Carlo simulation ass PK/PD index 40 % 100 % T &gt; MIC conduct result report % PTA ( Probability Target Attainment ) % CFR ( Cumulative Faction Response )</brief_summary>
	<brief_title>Population Pharmacokinetics Monte Carlo Dosing Simulations Meropenem During Early Phase Severe Sepsis Septic Shock Critically Ill Patients Intensive Care Units</brief_title>
	<detailed_description>Introduction : Severe sepsis/septic shock one important reason admission critically-ill patient Intensive Care Units ( ICU ) remain major cause high mortality . Evidently , fluctuation pathophysiology , particularly early phase , condition may result PK alteration lead inadequate antibiotic dose standard treatment . Therefore , thearly phase treatment appropriate antimicrobial dos achieve pharmacodynamic target antimicrobial therapy crucial factor therapeutic . Meropenem , carbapenem antibiotic , β-lactam antimicrobial agent broad spectrum activity , coverage gram-negative bacteria include highly resistant pathogen instance ESBL-producing AmpC-mediated b-lactamase produce Enterobacteriaceae . This agent , common β-lactams , characterized time-dependent antimicrobial activity , exposure time free drug concentration remain minimum inhibitory concentration ( T &gt; MIC ) pharmacokinetic/pharmacodynamic ( PK/PD ) index best correlate efficacy . The majority previous PK/PDs study β-lactams critically ill patient mostly conduct steady-state period treatment early phase severe sepsis/septic shock still lack . Objectives : To study population PK meropenem ass probability target attainment ( PTA ) meropenem inthe initial phase severe sepsis septic shock patient order able optimize dose recommendation . Clinical laboratory data : Age , sex , body weight , electrolite , vitalsigns , APACHAE II score , BUN , Cr , blood culture Drug preparation administration : The dosage meropenem 1-h infusion 1g dilute 100 mL normal saline solution via infusion pump constant flow rate every 8 h ( q8h ) 16 hour . Study design : Prospective non-comparative studyof 9 patient initial 24 h severe sepsis septic shock . Each subject receive 1-h infusion 1 g q8h meropenem 16 hr . Monte Carlo simulation attempt analyze pharmacokinetics experimental data . Sample collection : Meropenem PK study carry administration first second dose meropenem ( 0-16 h start administration meropenem ) . Blood sample ( ca . 3 mL ) obtain direct venipuncture follow time : shortly ( time 0 ) 0.25 , 0.5 , 1 , 1.25 , 1.5 , 2 , 2.5 , 3 , 4 , 5 , 8 , 8.5 , 9 , 9.5 , 10 , 12 , 14 16 h start administration meropenem . All blood sample add heparinized tube , immediately store ice centrifuge 2000 × g 4◦C 10 min within 5 min . All plasma sample store -80◦C analysis within 1 week . Moropenem assay : The meropenem assay method Ozkan et al . ( Biomed Chromatogr , 2001 ) perform Department Medicine , Faculty Medicine . Duration study : Patients receive 1-h infusion 1 g q8h meropenem 16 hr . Pharmacokinetic pharmacodynamic analysis : Concentration meropenem plasma simulate Monte Carlo technique get PK/PD index ( 40 % 80 % PTA ) Sample size : Nine patient severe sepsis septic shock .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<criteria>1 . Patient age &gt; 18 year 2 . Patients diagnose severe sepsis septic shock , either admission ICU stay . Sepsis systemic response infection define two follow condition : body temperature &gt; 38 oC &lt; 36 oC ; heart rate &gt; 90 beat per min ; respiratory rate &gt; 20 breath per min PaCO2 &lt; 32 mmHg ; leucocyte count &gt; 12,000 cell/mm3 , &lt; 4,000 cell/mm3 10 % immature ( band ) form . Severe sepsis define sepsis associate organ dysfunction , hypoperfusion , hypotension ( systolic arterial pressure &lt; 90 mmHg , mean arterial pressure &lt; 70 mmHg reduction ≥40 mmHg baseline ) . Septic shock define severe sepsis associate hypotension despite adequate fluid resuscitation 1 . Patients pregnant . 2 . Patients documented hypersensitivity carbapenems .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>meropenem , early phase , severe sepsis septic shock , critically ill , population pharmacokinetics</keyword>
</DOC>